Results 31 to 40 of about 204,846 (354)
Triple-modality autoantibody reduction regimen.
Triple-modality autoantibody reduction regimen.
Vincent G. Valentine (7465325) +10 more
core +1 more source
Objectives In order to address the reliability of commercial assays to identify myositis-specific and -associated autoantibodies, we aimed to compare the results of two commercial immunoassays with the results obtained by protein immunoprecipitation ...
Sarah L. Tansley +3 more
semanticscholar +1 more source
Background: Autoimmune hemolytic anemia (AIHA) is an immunological disease caused by autoantibodies. Warm autoantibody mainly includes anti-IgG and anti-(IgG+C3d) type, which can cause direct antiglobulin test (DAT) positive.
He Ziyi, Hu Yingming, Cui Siping
doaj +1 more source
Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction, characterized by skeletal muscle weakness and fatigability.
K. Lazaridis, S. Tzartos
semanticscholar +1 more source
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
BackgroundNo medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality.
Tejaswini Kulkarni +10 more
doaj +1 more source
Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.
Pathogenic autoantibodies arise in many autoimmune diseases, but it is not understood how the cells making them evade immune checkpoints. Here, single-cell multi-omics analysis demonstrates a shared mechanism with lymphoid malignancy in the formation of ...
Mandeep Singh +32 more
semanticscholar +1 more source
Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits [PDF]
Background: In celiac disease gluten, the disease-inducing toxic component in wheat, induces the secretion of autoantibodies which are targeted against transglutaminase 2 (TG2). These autoantibodies are produced in the small-intestinal mucosa, where they
Markku Maki +31 more
core +1 more source
Immunoglobulin G (IgG) antibodies are major drivers of autoimmune pathology, but they are also used in the form of intravenous IgG (IVIg) therapy to suppress autoantibody activity. To identify the pathways underlying human autoantibody and IVIg activity,
Inessa Schwab, Anja Lux, Falk Nimmerjahn
doaj +1 more source
Comparison of clinical and laboratory characteristics in children with type 1 diabetes according to pancreatic autoantibodies [PDF]
Purpose:The purpose of this study was to determine whether there is any difference in the clinical and laboratory characteristics of patients with autoantibody-positive and patients with autoantibody-negative type 1 diabetes at initial presentation ...
Ji Hae Choi +4 more
doaj +1 more source
Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus [PDF]
There is controversy about the role of auto anti-bodies against desmoglein 3 (Dsg 3) in the pathogenesis of lichen planus (LP). The goal of this study is to detect desmoglein-3 auto-antibodies in lichen planus patients comparted to normal control persons
Abd-El Aziz El-Rifaie +3 more
doaj +1 more source

